Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Without new blood vessels, neoplasms cannot expand beyond a few millimeters, the point at which the diffusion of nutrients and the disposal of waste products become rate-limiting. Regulation of angiogenesis thus must be controlled at multiple levels. For instance, the VEGF family of heparin-binding proteins and their primary receptors, VEGFR-1 and VEGFR-2 (KDR), products of the flt-1 and the flk-1 gene, respectively, are required for angioblast differentiation and vasculogenesis, and specific VEGF isoforms play distinct roles in promoting endothelial growth and migration during angiogenesis. In addition, angiogenesis is profoundly affected by several members of the FGF family and their four receptors, and indeed, supplementing the media of endothelial cell cultures with basic FGF (FGF2) and heparin is now well established as a means to obtain optimal growth, migration, and capillary morphogenesis. In addition to producing proangiogenic factors, tumor cells also directly or indirectly generate negative angiogenic stimuli. The ultimate growth rate of the tumors is thus a fine balance between positive and negative angiogenic cues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 3×
“Endostatin inhibits FGF2-induced stimulation of endothelial cell growth and inhibits the growth and associated angiogenesis of lung carcinomas, melanomas, fibrosarcomas, and endotheliomas (37).”
BackgroundInfluentialFunctions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
MATRIX PROTEOGLYCANS: From Molecular Design to Cellular Function
Iozzo, R. V. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.609 · Cited by 1,637
Self-citationBrodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Specificities of heparan sulphate proteoglycans in developmental processes
Perrimon, N., & Bernfield, M. (2000) · Nature · doi:10.1038/35008000 · Cited by 714
Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin
Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., & Blundell, T. L. (2000) · Nature · doi:10.1038/35039551 · Cited by 704
Whitelock, J. M., Murdoch, A. D., Iozzo, R. V., & Underwood, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.10079 · Cited by 597
Self-citationNugent, M. A., & Iozzo, R. V. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00123-5 · Cited by 547
Self-citationAviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G., & Yayon, A. (1994) · Cell · doi:10.1016/0092-8674(94)90031-0 · Cited by 536
Interaction of endostatin with integrins implicated in angiogenesis
Rehn, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031564998 · Cited by 460
Cited by
The sweet and sour of cancer: glycans as novel therapeutic targets
Fuster, M. M., & Esko, J. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1649 · Cited by 1,383
Proteoglycan form and function: A comprehensive nomenclature of proteoglycans
Iozzo, R. V., & Schaefer, L. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.02.003 · Cited by 1,263
Self-citationFibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
The Structure of Glycosaminoglycans and their Interactions with Proteins
Gandhi, N. S., & Mancera, R. L. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00741.x · Cited by 1,034
Structure and function of the skeletal muscle extracellular matrix
Gillies, A. R., & Lieber, R. L. (2011) · Muscle & Nerve · doi:10.1002/mus.22094 · Cited by 1,021
Heparin and heparan sulfate: Structure and function
Rabenstein, D. L. (2002) · Natural Product Reports · doi:10.1039/b100916h · Cited by 870
Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall
Lindblom, P., Gerhardt, H., Liebner, S., Abramsson, A., Enge, M., Hellström, M., Bäckström, G., Fredriksson, S., Landegren, U., Nyström, H. C., et al. (2003) · Genes & Development · doi:10.1101/gad.266803 · Cited by 657
Taylor, K. R., & Gallo, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.05-4682rev · Cited by 639
Roles of heparan-sulphate glycosaminoglycans in cancer
Sasisekharan, R., Shriver, Z., Venkataraman, G., & Narayanasami, U. (2002) · Nature Reviews Cancer · doi:10.1038/nrc842 · Cited by 621
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis
Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis
Iozzo, R. V., & Sanderson, R. D. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01236.x · Cited by 569
Self-citationSulfotransferases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility
Chapman, E., Best, M. D., Hanson, S. R., & Wong, C. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300631 · Cited by 543
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
Ilan, N., Elkin, M., & Vlodavsky, I. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.06.004 · Cited by 524
Basement membrane proteoglycans: from cellar to ceiling
Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521
Self-citationHallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
The role of heparan sulphate in inflammation
Parish, C. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1918 · Cited by 495
Insight into the physiological functions of PDGF through genetic studies in mice
Betsholtz, C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.005 · Cited by 437
Controlled Growth Factor Delivery for Tissue Engineering
Tayalia, P., & Mooney, D. J. (2009) · Advanced Materials · doi:10.1002/adma.200900241 · Cited by 430
Heparan Sulfate: A Complex Polymer Charged with Biological Activity
Whitelock, J. M., & Iozzo, R. V. (2005) · Chemical Reviews · doi:10.1021/cr010213m · Cited by 410
Self-citationProteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Self-citationSulfatases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility
Hanson, S. R., Best, M. D., & Wong, C. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300632 · Cited by 362
Götte, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0739rev · Cited by 348
Endorepellin, a Novel Inhibitor of Angiogenesis Derived from the C Terminus of Perlecan
Mongiat, M., Sweeney, S. M., San Antonio, J. D., Fu, J., & Iozzo, R. V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210445200 · Cited by 341
Self-citationSarrazin, S., Adam, E., Lyon, M., Depontieu, F., Motte, V., Landolfi, C., Lortat-Jacob, H., Bechard, D., Lassalle, P., & Delehedde, M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.004 · Cited by 337
Fukushi, J.-I., Makagiansar, I. T., & Stallcup, W. B. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-03-0236 · Cited by 324
Heparan sulfate: growth control with a restricted sequence menu
Gallagher, J. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13713 · Cited by 319
Growth factor binding to the pericellular matrix and its importance in tissue engineering☆
MACRI, L., SILVERSTEIN, D., & CLARK, R. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.015 · Cited by 292
Regulation of angiogenesis by extracellular matrix
Sottile, J. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.07.002 · Cited by 288
Kerever, A., Schnack, J., Vellinga, D., Ichikawa, N., Moon, C., Arikawa-Hirasawa, E., Efird, J. T., & Mercier, F. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0082 · Cited by 287
GLYCOMICS APPROACH TO STRUCTURE-FUNCTION RELATIONSHIPS OF GLYCOSAMINOGLYCANS
Sasisekharan, R., Raman, R., & Prabhakar, V. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095745 · Cited by 278
Bix, G., Fu, J., Gonzalez, E. M., Macro, L., Barker, A., Campbell, S., Zutter, M. M., Santoro, S. A., Kim, J. K., Höök, M., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200401150 · Cited by 252
Self-citationBasement Membrane Proteoglycans: Modulators Par Excellence of Cancer Growth and Angiogenesis
Iozzo, R. V., Zoeller, J. J., & Nyström, A. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0069-0 · Cited by 222
Self-citationA current view of perlecan in physiology and pathology: A mosaic of functions
Gubbiotti, M. A., Neill, T., & Iozzo, R. V. (2017) · Matrix Biology · doi:10.1016/j.matbio.2016.09.003 · Cited by 216
Self-citationThe role of VEGF-A in glomerular development and function
Eremina, V., & Quaggin, S. E. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200401000-00002 · Cited by 194
Gonzalez, E. M., Reed, C. C., Bix, G., Fu, J., Zhang, Y., Gopalakrishnan, B., Greenspan, D. S., & Iozzo, R. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409841200 · Cited by 190
Self-citationMongiat, M., Fu, J., Oldershaw, R., Greenhalgh, R., Gown, A. M., & Iozzo, R. V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210529200 · Cited by 177
Self-citationElgundi, Z., Papanicolaou, M., Major, G., Cox, T. R., Melrose, J., Whitelock, J. M., & Farrugia, B. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01482 · Cited by 176
Joyce, J. A., Freeman, C., Meyer-Morse, N., Parish, C. R., & Hanahan, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208602 · Cited by 163
Yang, H. S., Shin, J., Bhang, S. H., Shin, J.-Y., Park, J., Im, G.-I., Kim, C.-S., & Kim, B.-S. (2011) · Experimental and Molecular Medicine · doi:10.3858/emm.2011.43.11.070 · Cited by 147
Lord, M. S., Chuang, C. Y., Melrose, J., Davies, M. J., Iozzo, R. V., & Whitelock, J. M. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.01.016 · Cited by 130
Self-citationStructural characterization of human liver heparan sulfate
Vongchan, P., Warda, M., Toyoda, H., Toida, T., Marks, R. M., & Linhardt, R. J. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.09.007 · Cited by 65
Parkin, J. D., San Antonio, J. D., Persikov, A. V., Dagher, H., Dalgleish, R., Jensen, S. T., Jeunemaitre, X., & Savige, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0175582 · Cited by 39
Metadata
- Authors
- Iozzo, R. V., & San Antonio, J. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-08-01
- Volume
- 108
- Issue
- 3
- Pages
- 349-355
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2029176649
- Cited by
- 455
- References
- 44
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.